End-To-End Process for Improved Purity, Combined With Innovative Analytics of LNP-Based Therapeutics

End-To-End Process for Improved Purity, Combined With Innovative Analytics of LNP-Based Therapeutics

The poster presents an integrated end‑to‑end manufacturing and analytical strategy for lipid nanoparticle (LNP)–based genetic medicines, covering plasmid DNA (pDNA) production, mRNA synthesis, and final LNP drug substance. The overall objective is to establish a robust, scalable process that consistently delivers highly pure, functionally active LNPs while enabling detailed process understanding through advanced chromatography‑based process analytical technology (PAT). Such a framework is highly relevant for the development of mRNA vaccines, gene‑editing modalities, and cell‑based therapies.